ENTECAVIR VS. TENOFOVIR ON THE RISK OF HCC IN A US COHORT WITH CHRONIC HEPATITIS B VIRUS

被引：0
|
作者：
El-Serag, Hashem B. [1 ]
Richardson, Peter A. [2 ]
Kim, Hyun-Seok [3 ]
Hsu, Yao-Chun [4 ]
Kanwal, Fasiha [1 ,5 ,6 ]
Kramer, Jennifer [6 ,7 ]
机构：
[1] Baylor Coll Med, Sect Gastroenterol & Hepatol, Dept Med, Houston, TX 77030 USA
[2] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA
[3] Baylor Coll Med, Gastroenterol, Houston, TX 77030 USA
[4] Fu Jen Catholic Univ Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, New Taipei, Taiwan
[5] Michael E Debakey VA Med Ctr, Houston, TX 77030 USA
[6] Michael E Debakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety IQuESt, Houston, TX 77030 USA
[7] Baylor Coll Med, Med, Houston, TX 77030 USA
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
61
引用
下载
收藏
页码：43A / 43A
页数：1
相关论文
共 50 条
  • [1] Comparative Effectiveness of Tenofovir vs. Entecavir in Reducing the Risk of Hepatocellular Carcinoma in a US Cohort of Patients with Chronic Hepatitis B Virus Infection
    Kramer, Jennifer R.
    Mittal, Sahil
    Richardson, Peter
    El-Serag, Hashem B.
    Kanwal, Fasiha
    HEPATOLOGY, 2015, 62 : 335A - 336A
  • [2] COMPARATIVE EFFECTIVENESS OF TENOFOVIR VS. ENTECAVIR IN REDUCING THE RISK OF HEPATOCELLULAR CARCINOMA IN A US COHORT OF PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION
    Kramer, Jennifer R.
    Kim, Hyunseok
    Christie, Israel
    Richardson, Peter
    El-Serag, Hashem B.
    Kanwal, Fasiha
    GASTROENTEROLOGY, 2020, 158 (06) : S1320 - S1320
  • [3] The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus
    Kramer, Jennifer R.
    Richardson, Peter A.
    Kim, Hyunseok
    Hsu, Yao-Chun
    Kanwal, Fasiha
    El-Serag, Hashem B.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (04) : 1111 - 1113
  • [4] Chronic HBV-Infection: lower risk of HCC with Tenofovir vs. Entecavir
    Lichert, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (04): : 310 - 310
  • [5] Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Lee, Hye Won
    Cho, Young Youn
    Lee, Hyein
    Lee, Jae Seung
    Kim, Seung Up
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Kim, Beom Kyung
    Park, Soo Young
    HEPATOLOGY INTERNATIONAL, 2021, 15 (05) : 1083 - 1092
  • [6] Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee
    Young Youn Cho
    Hyein Lee
    Jae Seung Lee
    Seung Up Kim
    Jun Yong Park
    Do Young Kim
    Sang Hoon Ahn
    Beom Kyung Kim
    Soo Young Park
    Hepatology International, 2021, 15 : 1083 - 1092
  • [7] Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B
    Lee, Han Ah
    Seo, Yeon Seok
    Kim, Seung Up
    GASTROENTEROLOGY, 2020, 158 (08) : 2310 - 2311
  • [8] Comparison of HCC incidence between entecavir and tenofovir in a chronic hepatitis B cohort with balanced censoring
    Jung, Jang Han
    Yoon, Eileen
    Jun, Dae Won
    Oh, Hyunwoo
    Lee, Hyo Young
    Kim, Sung Eun
    Kim, Sung-Eun
    Jeong, Soung Won
    Kim, Gi-Ae
    An, Jihyun
    Sohn, Joo Hyun
    Sohn, Won
    Cho, Yong Kyun
    Ahn, Sang Bong
    JOURNAL OF HEPATOLOGY, 2023, 78 : S1073 - S1073
  • [9] Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B
    Liu, Zhihong
    Sun, Jian
    Hou, Jinlin
    JAMA ONCOLOGY, 2019, 5 (06) : 915 - 915
  • [10] Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B Reply
    Choi, Jonggi
    Ko, Min Jung
    Lim, Young-Suk
    JAMA ONCOLOGY, 2019, 5 (06) : 916 - 917
12345